Phaseline

Companies › MegaPro Biomedical

MegaPro Biomedical: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Oncology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
MPB-1734–Phase 1Solid Tumor, Unspecified, Adult–
MPB-2043
Superparamagnetic iron oxide (SPIO) MRI contrast agent
–Phase 1Head and Neck Squamous Cell Carcinoma–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04643418MPB-1734Phase 1Solid Tumor, Unspecified, AdultOncologyMar 2025
NCT06540443MPB-2043Phase 1Head and Neck Squamous Cell CarcinomaOncologyJun 2026

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.